EHA 2026 | Insights into emerging treatment options for Ph+ ALL: TKI and immunotherapy combinations.
Ilaria Iacobucci
• 12 Jun 2026
Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, discusses recent advancements in treatment options for patients with Ph+ acute lymphoblastic leukemia (ALL). Dr Iacobucci highlights promising results from combining tyrosine kinase inhibitors (TKIs), such as ponatinib, with immunotherapies like blinatumomab, which have led to improved complete remission rates and reduced adverse prognostic markers. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
